EUVIMEDEUVIMED entdecken
Crossref

Development of Alcohol-Resistant Extended-Release Formulations: Regulatory Considerations and Formulation Strategies

Ming Ji, Nitin K Swarnakar, Shanmuka Harish Chalamuri, Kalyan Kathala, Sandip Tiwari

Pharmaceutical Research · 2025

DOI: 10.1007/s11095-025-03968-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Research, 2025. Verfasst von Ming Ji und 4 weiteren Autor:innen. Beteiligte Einrichtung: BASF Corp., Tarrytown, NY, 10591, USA. Hauptthemen laut MEDLINE: Delayed-Action Preparations, Povidone. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: This study was aimed to develop reservoir-type extended-release (ER) formulations resistant to alcohol-induced dose dumping (ADD) using polyvinyl acetate (PVAc) and polyvinylpyrrolidone (PVP-90). METHODS: The ER formulations were developed utilizing water-soluble and water-insoluble core diluents and binders, along with various PVAc with PVP-90 (3:1 w/w) coating levels. In vitro risk mitigation studies were conducted to understand the impact of alcohol on the properties of polymer compositions and their films, including viscosity, swelling, elasticity, and breaking force. The PVAc with PVP-90 (3:1) film exhibited minimal swelling and maintained better integrity in the presence of alcohol. RESULTS: The ER tablets incorporating water-soluble L-PVP in the core did not exhibit burst release in alcoholic media but showed compromised ADD resistance at lower coating levels. Increasing the concentration of PVP-90 in the core resulted in a slower disintegration rate, with concentrations exceeding 15% preventing full disintegration of tablets within 2 h in 0.1N HCl with 40% alcohol. The optimized formulation, containing 25% PVP-90 in the core and PVAc with PVP-90 coating, minimized ADD risk and maintained an ER release profile even after exposure to accelerated storage conditions (40°C/75% RH) for 3 months. CONCLUSION: The study highlights the importance of core and coating compositions in achieving ADD resistance. However, risk mitigation strategies including a new recommended dissolution method revealed that formulations meeting FDA guidelines could still exhibit dose dumping after just 2 h of alcohol exposure. This finding suggests the need to review regulatory standards for ADD resistance and harmonize requirements between agencies like EMA and US FDA to develop a relevant in vitro method for assessing ADD in modified release formulations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Delayed-Action PreparationsPovidoneChemistry, PharmaceuticalSolubilityExcipientsTabletsDrug CompoundingDrug LiberationPolyvinylsViscosity

Stichwörter der Autor:innen

ADD guidelinealcohol resistencealcohol-induced dose dumping (ADD)polyvinyl acetate (PVAc) dispersionpolyvinylpyrrolidone (PVP) 90reservoir-type extended-release formulationsustained release coating

Substanzen

Delayed-Action PreparationsPovidonepolyvinyl acetateExcipientsTabletsPolyvinyls

Autor:innen und Institutionen

  • BASF Corp., Tarrytown, NY, 10591, USA.
  • BASF Corp., Tarrytown, NY, 10591, USA. nitin.swarnakar@basf.com.
  • Tulex Pharmaceuticals, Cranbury, NJ, 08512, USA.

Zitieren

APA

Ji, M., Swarnakar, N. K., Harish Chalamuri, S., Kathala, K., & Tiwari, S. (2025). Development of Alcohol-Resistant Extended-Release Formulations: Regulatory Considerations and Formulation Strategies. Pharmaceutical Research. https://doi.org/10.1007/s11095-025-03968-3

Vancouver

Ji M, Swarnakar NK, Harish Chalamuri S, Kathala K, Tiwari S. Development of Alcohol-Resistant Extended-Release Formulations: Regulatory Considerations and Formulation Strategies. Pharmaceutical Research. 2025. doi:10.1007/s11095-025-03968-3

BibTeX
@article{Ji2025,
  author = {Ji, Ming and Swarnakar, Nitin K and Harish Chalamuri, Shanmuka and Kathala, Kalyan and Tiwari, Sandip},
  title = {Development of Alcohol-Resistant Extended-Release Formulations: Regulatory Considerations and Formulation Strategies},
  journal = {Pharmaceutical Research},
  year = {2025},
  doi = {10.1007/s11095-025-03968-3}
}
Kostenlos starten →